|
1) Sandborn WJ. Current direction in IBD therapy: What goals are feasible with biologic modifiers？ Gastroenterology. 2008; 135: 1442-7
|
|
|
|
|
2) 松本譽之. 潰瘍性大腸炎・クローン病治療指針改訂. 難治性炎症性腸管障害に関する調査研究平成21年度総括・分担研究報告書. 2010. p.37-43
|
|
|
|
|
|
3) Peyrin-Biroulet L, Deltenre P, de Suray N, et al. Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials. Clin Gastroenterol Hepatol. 2008; 6: 644-53
|
|
|
|
|
4) Ford AC, Sandborn WJ, Khan KJ, et al. Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol. 2011; 106: 644-59
|
|
|
|
|
|
5) D'Haens G, Baert F, van Assche G, et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet. 2008; 371: 660-7
|
|
|
|
|
|
6) Burger D, Travis S. Conventional medical management of inflammatory bowel disease. Gastroenterology. 2011; 140: 1827-37
|
|
|
|
|
|
7) Loly C, Belaiche J, Louis E. Predictors of severe Crohn's disease, Scand J Gastroenterol. 2008; 43: 948-54
|
|
|
|
|
|
8) D'Haens G, Panaccione R, Higgins PD, et al. The London Position Statement of the World Congress of Gastroenterology on biological therapy for IBD with the European Crohn's and Colitis Organisation: when to start, when to stop, which drug to choose and how to predict response？ Am J Gastroenterol. 2011; 106: 199-212
|
|
|
|
|
|
9) Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med. 2010; 362: 1383-95
|
|
|
|
|
|
10) Bruining DH, Sandborn WJ. Do not assume symptoms indicate failure of anti-tumor necrosis factor therapy in Crohn's disease. Clin Gastro Hepatol. 2011; 9: 395-9
|
|
|
|
|
|
11) Baert F, Moortgat L, Van Assche G, et al. Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's disease. Gastroenterology. 2010; 138: 463-8
|
|
|
|
|
|
12) Schnitzler F, Fidder H, Ferrante M, et al. Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort. Gut. 2009; 58: 492-500
|
|
|
|
|
|
13) Afif W, Loftus EV Jr, Faubion WA, et al. Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease. Am J Gastroenterol. 2010; 105: 1133-9
|
|
|
|
|
|
14) Sandborn WJ, Rutgeerts P, Enns R, et al. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med. 2007; 146: 829-38
|
|
|
|
|
|
15) Allez M, Vermeire S, Mozziconacci N, et al. The efficacy and safety of a third anti-TNF monoclonal antibody in Crohn's disease after failure of two other anti-TNF antibodies. Aliment Pharmacol Ther. 2010; 31: 92-101
|
|
|
|
|
|
16) 長堀正和, 玄 世峰, 渡辺 守. クローン病におけるthiopurine 併用infliximab計画的維持投与例の検討と維持困難例でのmethotrexateの有用性. 日消誌. 2010; A485
|
|
|
|
|
|
17) 山本壽恵, 木村英明, 国崎玲子. 当院におけるTacrolimusによるinfliximab抵抗性クローン病に対する治療成績. 日消誌. 2010; A602
|
|
|
|
|
18) Panaccione R, Colombel JF, Sandborn WJ, et al. Adalimumab sustains clinical remission and overall clinical benefit after 2 years of therapy for Crohn's disease. Aliment Pharmacol Ther. 2010; 31: 1296-309
|
|
|
|
|
|
19) Kamm MA, Hanauer SB, Panaccione R, et al. Adalimumab sustains steroid-free remission after 3years of therapy for Crohn's disease. Aliment Pharmacol Ther. 2011; 34: 306-17
|
|
|
|
|
|
20) Colombel JF, Schwartz DA, Sandborn WJ, et al. Adalimumab for the treatment of fistulas in patients with Crohn's disease. Gut. 2009; 58; 940-8
|
|
|
|
|
|
21) Lichtiger S, Binion DG, Wolf DC, et al. The CHOICE trial: adalimumab demonstrates safety, fistula healing, improved quality of life and increased work productivity in patients with Crohn's disease who failed prior infliximab therapy. Aliment Pharmacol Ther. 2010; 32: 1228-39
|
|
|
|
|
|
22) Karmiris K, Paintaud G, Noman M, et al. Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn's disease. Gastroenterology. 2009; 137: 1628-40
|
|
|
|
|
|
23) Toruner M, Loftus Jr EV, Harmsen WS, et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease, Gastroenterology. 2008; 134: 929-36
|
|
|
|
|
|
24) Cottone M, Kohn A, Daperno M, et al. Advanced age is an independent risk factor for severe infections and mortality in patients given anti-tumor necrosis factor therapy for inflammatory bowel disease. Clin Gastroenterol Hepatol. 2011; 9: 30-5
|
|
|
|
|
|
25) Siegel CA, Marden SM, Persing SM, et al. Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: a meta-analysis. Clin Gastroenterol Hepatol. 2009; 7: 874-81
|
|
|
|
|
|
26) Beaugerie L, Brousse N, Bouvier AM, et al. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet. 2009; 374: 1617-25
|
|
|
|
|
|
27) Kotlyar DS, Osterman MT, Diamond RH, et al. A systematic review of factors that contribute to hepatosplenic T-cell lymphoma in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2011; 9: 36-41
|
|
|
|
|
|
28) Gottlieb A, Menter A, Mendelsohn A, et al. Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial. Lancet. 2009; 373: 633-40
|
|
|
|
|
|
29) Panaccione R, Sandborn W, Gordon G, et al. Briakinumab (anti-interleukin 12/23p40, ABT874) for treatment of Crohn's disease. Am J Gastroenterol. 2010; 105: S1245
|
|
|
|
|